Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Blood (2023) 142 (Supplement 1): 2011.

https://doi.org/10.1182/blood-2023-180013

Published: 2023

Journal Articles

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Agnese Mattei, Giovanni Marconi, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Claudio Cerchione, Irene Zacheo, Maria Benedetta Giannini, Marianna Norata, Giovanni Martinelli, Anna Ferrari, Maria Teresa Bochicchio, Martina Ghetti, Matteo Marchesini, Giorgia Simonetti, Gerardo Musuraca, Davide Nappi

Blood (2023) 142 (Supplement 1): 1475.

https://doi.org/10.1182/blood-2023-186760

Published: 2023

Journal Articles

Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study

Antonio Frolli, Claudio Cerchione, Riccardo Staiano, Tommasina Guglielmelli, Davide Nappi, Agnese Mattei, Silvia Marini, Daniela Cilloni, Guido Eugenio Parvis

Blood (2023) 142 (Supplement 1): 6656.

https://doi.org/10.1182/blood-2023-190212

Published: 2023

Journal Articles

Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

Adolfo De La Fuente Burguera, Claudio Cerchione, Sebastian Scholl, Jan Moritz Middeke, Gaurav S Choudhary, Reinhard von Roemeling, Uwe Platzbecker

Blood (2023) 142 (Supplement 1): 5975.

https://doi.org/10.1182/blood-2023-190125

Published: 2023

Journal Articles

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione, Davide Nappi, Gerardo Musuraca, Sonia Ronconi, Delia Cangini, Michela Ceccolini, Giovanni Martinelli

Blood (2022) 140 (Supplement 1): 13248–13249.

https://doi.org/10.1182/blood-2022-170561

Published: 2022

Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 m ND-AML Treated with Ivo+AZA in the AGILE Study

Blood (2022) 140 (Supplement 1): 539–542.

https://doi.org/10.1182/blood-2022-159473

Published: 2022

Journal Articles

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Blood (2022) 140 (Supplement 1): 400–402.

https://doi.org/10.1182/blood-2022-159009

Published: 2022

Journal Articles

Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era

Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, Sonia Ronconi, Michela Ceccolini, Giovanni Martinelli, Fabrizio Pane

Blood (2022) 140 (Supplement 1): 12585–12586.

https://doi.org/10.1182/blood-2022-170484

Published: 2022

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Giovanni Martinelli

Blood (2021) 138 (Supplement 1): 5022.

https://doi.org/10.1182/blood-2021-153971

Published: 2021

Journal Articles

Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated Multiple Myeloma: Old PLUS New Drugs in NOVEL Agents' Era

Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Giovanni Martinelli

Blood (2021) 138 (Supplement 1): 5021.

https://doi.org/10.1182/blood-2021-153954

Published: 2021

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Claudio Cerchione, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Lucio Catalano, Giovanni Martinelli

Blood (2021) 138 (Supplement 1): 5020.

https://doi.org/10.1182/blood-2021-153933

Published: 2021

Journal Articles

Erythropoiesis Stimulating Agents (ESAS) in Supportive Care of Low-Risk Myelodysplastic Syndromes: Recamds Registry FINAL Results

Claudio Cerchione, Fiorella Alfinito, Orsola Vitagliano, Ilaria Soriente, Paolo Danise, Giuseppe Cerciello, Fabrizio Pane, Giovanni Martinelli

Blood (2021) 138 (Supplement 1): 5038.

https://doi.org/10.1182/blood-2021-153793

Published: 2021

Journal Articles

Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma

Fabrizio Puglisi, Antonella Padella, Nunziatina Laura Parrinello, Grazia Scandura, Daniela Cambria, Enrico La Spina, Alessandro Barbato, Cesarina Giallongo, Daniele Tibullo, Giuseppe A. Palumbo, Claudio Cerchione, Giovanni Martinelli, Giorgia Simonetti, Francesco Di Raimondo, Alessandra Romano

Blood (2021) 138 (Supplement 1): 4497.

https://doi.org/10.1182/blood-2021-151006

Published: 2021

Journal Articles

Role of Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Fabrizio Pane, Giovanni Martinelli

Blood (2021) 138 (Supplement 1): 4760.

https://doi.org/10.1182/blood-2021-153877

Published: 2021

Journal Articles

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Blood (2020) 136 (Supplement 1): 32–34.

https://doi.org/10.1182/blood-2020-139981

Published: 2020

Journal Articles

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-143178

Published: 2020

Journal Articles

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Sonia Ronconi, Michela Ceccolini, MD, Delia Cangini, Maria Benedetta Giannini, MD, Valeria Di Battista, Giorgia Simonetti, PhD, Andrea Ghelli Luserna Di Rorà, PhD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-143143

Published: 2020

Journal Articles

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Fabrizio Pane, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 2.

https://doi.org/10.1182/blood-2020-143189

Published: 2020

Journal Articles

Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era

Claudio Cerchione, MD PhD, Lucio Catalano, Davide Nappi, Stefano Rocco, Salvatore Palmieri, Anna Emanuele Pareto, Gerardo Musuraca, MD, Alessandro Lucchesi, MD, Fabrizio Pane, Felicetto Ferrara, MD, Giovanni Martinelli, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-143207

Published: 2020

Journal Articles

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-143082

Published: 2020

NARROW

Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2+1 B-Cell Maturation Antigen (BCMA) × CD3 T-Cell Engager (TCE), Administered Subcutaneously (SC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from a Phase 1 First-in-Human Clinical Study

Pre-Existing Myeloid Subclones May Account for a Subset of Acute Myeloid Leukemias and Myelodysplastic Neoplasms in Patients with Pre-Existing or Contemporary Lymphoid Disorders

Safety and Efficacy of New Drugs Combinations in Newly Diagnosed Multiple Myeloma with Renal Failure at Onset: A Retrospective Multicentric Study

Trial in Progress: A Phase 1b Single-Arm, Open-Label Study of Emavusertib (CA-4948) in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 m ND-AML Treated with Ivo+AZA in the AGILE Study

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Chemo or Chemo-Free Regimens in Heavily Pretreated Multiple Myeloma? Role of Bendamustine-Bortezomib-Dexamethasone (BVD) in NOVEL Agents' Era

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Bendamustine-Bortezomib-Dexamethasone in Heavily Pretreated Multiple Myeloma: Old PLUS New Drugs in NOVEL Agents' Era

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Erythropoiesis Stimulating Agents (ESAS) in Supportive Care of Low-Risk Myelodysplastic Syndromes: Recamds Registry FINAL Results

Dissecting the Adaptive Response to Arginine Deprivation in Hodgkin Lymphoma

Role of Pegfilgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

A Preliminary Analysis of FLAM (Italian Non-Interventional Multi-center Study of FLT3 mutated AML patients): FLT3 Receptor Gene Mutational Analysis and FLT3 Inhibitors Administration in the Real-Life Clinical Practice

Pegfilgrastim Versus Filgrastim in the Supportive Care of Heavily Pretreated Multiple Myeloma in Treatment with Pomalidomide-Dexamethasone

Pomalidomide-Dexamethasone in the Management of Heavily Pretreated Multiple Myeloma

Carfilzomib-Lenalidomide-Dexamethasone in the Management of Lenalidomide-Refractory Multiple Myeloma

Bendamustine-Bortezomib-Dexamethasone (BVD) in Heavily Pretreated Multiple Myeloma: Old/New in NOVEL Agents' Era

Italian Observational Study on Real-Life Use of Venetoclax in Acute Myeloid Leukemia (AVALON study): Results of Interim Analysis on Relapsed/Refractory Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only